Bactiguard expands in the Middle East
Bactiguard signs distribution agreement and enters partnership with Heal Pharma for Egypt. The product registration has been initiated and market launch is planned for the second quarter of 2017.
“Egypt is the most populous country in the Arab world, with major challenges in the healthcare sector. We are convinced that Bactiguard’s portfolio of products and services for reducing hospital acquired infections, combined with our partner’s extensive network and competence, will make this market one of our biggest in the region in a few years”, says Christian Kinch, CEO.
“We are excited about the partnership with Bactiguard. Their innovative technology meets an obvious need in the Egyptian market, where one of biggest challenges is serious infections in combination with extensive use of antibiotics. By offering a solution that prevents infections, we can increase patient safety and reduce the use of antibiotics as well as hospitalization time and, thereby, increase the efficiency of the healthcare system”, says Dr Mohamed Khalifa, Chairman of Heal Pharma.
Egypt is the most populous country in North Africa and the Middle East, with a population of approximately 90 million. Heal Pharma, based in Cairo, has a nationwide reach and was established in 2008 by Dr Mohamed Khalifa.
The agreement was signed in the presence of the Swedish Ambassador to the United Arab Emirates, Jan Thesleff, and Niclas Jacobson from the Swedish Ministry of Social Affairs at Arab Health in Dubai. For the tenth year in a row, Bactiguard participates with its own personnel and a booth at this annual international trade exhibition.
For further information, please contact:
Cecilia Edström, SVP Sales & New business, cell phone: +46 72 226 23 28
Bactiguard is a Swedish medtech company with a global presence, offering a solution that prevents healthcare associated infections caused by medical devices. By preventing infections, we contribute to a reduced use of antibiotics and the spread of multi-resistant bacteria, which is a growing problem worldwide. We save lives, increase patient safety and significantly reduce the cost for the healthcare and society. Our technology is well-proven, safe and tissue friendly and consist of a thin layer of noble metals that prevents bacterial growth. The coating can be applied on almost all medical devices. Bactiguard-coated urinary catheters are market leading in the US and Japan and the company has also its own product portfolio consisting of Foley catheters, central venous catheters and endotracheal tubes. Bactiguard is a growth company, focused on markets in Europe, Middle East, Asia and Latin America. The company has about 60 employees worldwide, mainly at the headquarters in Stockholm and the production facility in Malaysia and is listed on Nasdaq Stockholm. Read more about Bactiguard at www.bactiguard.com